###begin article-title 0
###xml 111 116 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tat-SF1 Is Not Required for Tat Transactivation but Does Regulate the Relative Levels of Unspliced and Spliced HIV-1 RNAs
###end article-title 0
###begin p 1
Conceived and designed the experiments: HM KS GT MGB. Performed the experiments: HM KS. Analyzed the data: HM KS GT MGB. Wrote the paper: HM KS GT MGB.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 161 169 161 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 433 440 433 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 74 79 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 relies on several host proteins for productive viral transcription. HIV-1 Tat-specific factor 1 (Tat-SF1) is among these cofactors that were identified by in vitro reconstituted transcription reactions with immunodepleted nuclear extracts. At the onset of this work, the prevailing hypothesis was that Tat-SF1 was a required cofactor for the viral regulatory protein, Tat; however, this had not previously been formally tested in vivo.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 50 55 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 330 335 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 493 498 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To directly address the involvement of Tat-SF1 in HIV-1 gene expression, we depleted Tat-SF1 in HeLa cells by conventional expression of shRNAs and in T- Rex -293 cells containing tetracycline-inducible shRNAs targeting Tat-SF1. We achieved efficient depletion of Tat-SF1 and demonstrated that this did not affect cell viability. HIV-1 infectivity decreased in Tat-SF1-depleted cells, but only when multiple rounds of infection occurred. Neither Tat-dependent nor basal transcription from the HIV-1 LTR was affected by Tat-SF1 depletion, suggesting that the decrease in infectivity was due to a deficiency at a later step in the viral lifecycle. Finally, Tat-SF1 depletion resulted in an increase in the ratio of unspliced to spliced viral transcripts.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 39 44 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 127 132 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 229 234 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tat-SF1 is not required for regulating HIV-1 transcription, but is required for maintaining the ratios of different classes of HIV-1 transcripts. These new findings highlight a novel, post-transcriptional role for Tat-SF1 in the HIV-1 life cycle.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 198 201 198 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Jones1">[1]</xref>
###xml 203 206 203 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Cullen1">[2]</xref>
###xml 208 211 208 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Cullen2">[3]</xref>
###xml 213 216 213 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Goff1">[4]</xref>
###xml 352 355 352 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Jones2">[5]</xref>
###xml 357 360 357 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Wei1">[6]</xref>
###xml 362 365 362 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Herrmann1">[7]</xref>
###xml 367 370 367 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Herrmann2">[8]</xref>
###xml 372 375 372 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Isel1">[9]</xref>
###xml 377 381 377 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Mancebo1">[10]</xref>
###xml 383 387 383 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Taube1">[11]</xref>
###xml 389 393 389 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Yang1">[12]</xref>
###xml 530 533 530 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Cullen1">[2]</xref>
###xml 535 538 535 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Jones2">[5]</xref>
###xml 642 645 642 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Wei1">[6]</xref>
###xml 746 750 746 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Bieniasz1">[13]</xref>
###xml 943 946 943 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Herrmann1">[7]</xref>
###xml 948 951 948 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Herrmann2">[8]</xref>
###xml 953 956 953 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Isel1">[9]</xref>
###xml 958 962 958 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Mancebo1">[10]</xref>
###xml 964 968 964 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Zhou1">[14]</xref>
###xml 970 974 970 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Dahmus1">[15]</xref>
###xml 4 39 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 292 297 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 412 417 <span type="species:ncbi:9606">human</span>
The human immunodeficiency virus type 1 (HIV-1), like all other complex retroviruses, tightly regulates transcription from its genome. This regulation is mediated by both viral and cellular factors [1], [2], [3], [4]. The viral regulatory protein, Tat, stimulates transcription elongation of HIV-1 through a series of events termed Tat transactivation [5], [6], [7], [8], [9], [10], [11], [12]. Tat recruits the human positive transcription elongation factor b (P-TEFb) to the TAR RNA element at the 5' end of nascent transcripts [2], [5]. Tat interacts directly with cyclin T1 (CCNT1), a component of P-TEFb, which allows recognition of TAR [6]. P-TEFb recruitment has been proposed to be necessary and sufficient for transcriptional elongation [13]. The CDK9 kinase activity of P-TEFb results in hyperphosphorylation of the carboxyl-terminus domain (CTD) of the largest subunit of RNA Polymerase II (RNAPII), leading to efficient elongation [7], [8], [9], [10], [14], [15].
###end p 9
###begin p 10
###xml 304 308 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Zhou2">[16]</xref>
###xml 310 314 310 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Sune1">[17]</xref>
###xml 316 320 316 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Parada1">[18]</xref>
###xml 437 445 437 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 445 449 445 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Zhou2">[16]</xref>
###xml 451 455 451 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Parada1">[18]</xref>
###xml 457 461 457 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Li1">[19]</xref>
###xml 463 467 463 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-WuBaer1">[20]</xref>
###xml 605 613 605 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 665 669 665 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Parada1">[18]</xref>
###xml 671 675 671 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Zhou3">[21]</xref>
###xml 841 849 841 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTAT-SF1</italic>
###xml 953 957 953 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Zhou2">[16]</xref>
###xml 959 963 959 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Parada1">[18]</xref>
###xml 965 969 965 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Li1">[19]</xref>
###xml 1053 1057 1053 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Zhou2">[16]</xref>
###xml 1218 1222 1218 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Zhou2">[16]</xref>
###xml 1371 1375 1371 1375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Kim1">[22]</xref>
###xml 1527 1535 1527 1535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1540 1547 1540 1547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 53 58 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 226 231 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 585 590 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Many groups have investigated the mechanism by which HIV-1 utilizes P-TEFb as a cellular cofactor for Tat transactivation. These studies suggest that P-TEFb is part of a multiprotein complex that associates with RNAPII at the HIV-1 promoter and that other cellular factors also assist in transactivation [16], [17], [18]. Previous studies have used nuclear extract fractions from Tat affinity columns to reconstitute Tat transactivation in vitro[16], [18], [19], [20]. One of these studies identified a cellular activity that was required for Tat-specific, TAR-dependent activation of HIV-1 transcription in vitro, and it was termed Tat stimulatory factor (Tat-SF) [18], [21]. Further affinity purification of this activity identified a novel, 140-kDa protein that was sequenced and named Tat-SF1 (accession number NP_055315; HUGO gene name HTAT-SF1). Immunodepletion of this protein from nuclear extracts resulted in a reduction in Tat transactivation [16], [18], [19], and overexpression of Tat-SF1 resulted in a small increase in Tat transactivation [16]. The increase in Tat transactivation, however, was primarily due to a decrease in basal transcription, and only a small increase in Tat-dependent transcription [16]. In addition to the usual caveats of overexpression data, this result was not recapitulated by the same group when using a different plasmid system [22]. These studies, which used the best technology available at the time, justifiably concluded that Tat-SF1 was a likely cofactor for Tat transactivation in vitro and in vivo.
###end p 10
###begin p 11
###xml 65 69 65 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Parada1">[18]</xref>
###xml 71 75 71 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Li1">[19]</xref>
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Zhou1">[14]</xref>
###xml 205 209 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Zhou1">[14]</xref>
###xml 211 215 211 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Fong1">[23]</xref>
###xml 322 326 322 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Kim1">[22]</xref>
###xml 568 572 568 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Parada1">[18]</xref>
###xml 739 743 739 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-SanchezAlvarez1">[24]</xref>
###xml 426 431 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 529 534 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tat-SF1 has also been proposed to be a general elongation factor [18], [19]. It can associate with Tat:P-TEFb transcription elongation complexes in nuclear extracts [14] through a direct CCNT1 interaction [14], [23]. Two other transcription elongation factors, hSPT5 and the RAP30 protein of TFIIF, associate with Tat-SF1 [22]. Tat-SF1 has been shown to be a component of an RNAPII-containing complex that also contains other HIV-1 cellular cofactors such as P-TEFb and hSPT5, and these factors were shown to be recruited to the HIV-1 promoter in HeLa nuclear extract [18]. In a separate study, immunoprecipitation experiments showed that Tat-SF1, along with P-TEFb, TCERG1 (CA150), and TFIIF all associate in an RNAPII-containing complex [24].
###end p 11
###begin p 12
###xml 231 235 231 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Kameoka1">[25]</xref>
###xml 457 461 456 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Fong2">[26]</xref>
###xml 568 572 567 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Yan1">[27]</xref>
###xml 702 706 701 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Fong2">[26]</xref>
###xml 855 859 854 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Smith1">[28]</xref>
###xml 477 482 <span type="species:ncbi:4932">yeast</span>
In addition to the associations with transcription factors, Tat-SF1 has also been found to interact with several components of the spliceosome. Large RNAP II-containing complexes that associate with 5'-splice sites contain Tat-SF1 [25]. Tat-SF1 also interacts with snRNP proteins U1 70 K, U2B'', and Sm proteins B and B'. In addition, Tat-SF1 associates with all five spliceosomal U snRNAs, and this interaction depends on its RNA recognition motifs (RRMs) [26]. Moreover, the yeast homologue of Tat-SF1, CUS2, helps refold U2 snRNAs to aid in prespliceosome assembly [27]. The association with both elongation and splicing factors has led to the suggestion that Tat-SF1 can couple these two processes [26]. Indeed, another transcription-splicing coupling factor, TCERG1, binds Tat-SF1 directly through multiple interactions with FF domains in the former [28].
###end p 12
###begin p 13
###xml 108 116 108 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 317 324 317 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 299 304 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 396 401 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 676 681 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Insight into the role of Tat-SF1 in the HIV-1 lifecycle has previously been limited to immunodepletions and in vitro analyses or transient overexpression experiments. In this manuscript, we present studies that utilize RNA interference (RNAi) to reevaluate Tat-SF1's role in Tat transactivation and HIV-1 replication in vivo. We found that Tat-SF1 depletion did not affect transcription from the HIV-1 LTR and did not alter the overall level of viral transcripts; however, Tat-SF1 depletion resulted in a significant decrease in viral replication. This study demonstrates that the major effect upon knockdown of Tat-SF1 was a change in the ratio of unspliced to fully spliced HIV-1 RNAs. Based on our data, we propose a novel activity for Tat-SF1 as a post-transcriptional regulator of viral pre-mRNAs.
###end p 13
###begin title 14
Materials and Methods
###end title 14
###begin title 15
shRNA constructs
###end title 15
###begin p 16
###xml 251 270 251 270 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GAGTCAGATGACAAGGAAG</named-content>
###xml 291 310 291 310 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GAGAATCTGTGGAACTTGC</named-content>
###xml 500 522 500 522 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GGCCTTCTAGAGCAAGGCATTT</named-content>
###xml 1033 1081 1033 1081 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CCA TGG GGA TCC CAG CAC ATA TAC TAG TCG AC 3&#8242;</named-content>
###xml 1086 1136 1086 1136 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; CCA TGC GGC CGC TAA TTC AGC TTT GTA AAA ATG- 3&#8242;</named-content>
Two different short hairpin RNA (shRNA) sequences targeting Tat-SF1 transcripts in the pSuper vector backbone (OligoEngine) were gifts from Dr. Bryan Cullen (Duke University). Tat-SF1(A) consists of a hairpin targeting the following Tat-SF1 sequence: GAGTCAGATGACAAGGAAG. Tat-SF1(B) targets GAGAATCTGTGGAACTTGC. A third shRNA targeting Tat-SF1, Tat-SF1(C), was expressed from the pSM2 vector (Open Biosystems), obtained from the Duke RNAi Facility. Tat-SF1(C) targets the following Tat-SF1 sequence: GGCCTTCTAGAGCAAGGCATTT. The GFP targeting and non-silencing control shRNAs were also in pSM2. Empty pSuper, used as a negative control in transient knockdowns, was a gift from Dr. Vann Bennett (Duke University). To create tetracycline inducible shRNA constructs, hairpin sequences were subcloned from pSuper by digestion with BamH1 and XhoI and ligated into the corresponding sites in pcDNA5/FRT/TO (Invitrogen). Hairpin sequences targeting GFP and Tat-SF1 in the pSM2 vector were PCR amplified using the following oligonucleotides: 5'-CCA TGG GGA TCC CAG CAC ATA TAC TAG TCG AC 3' AND 5' CCA TGC GGC CGC TAA TTC AGC TTT GTA AAA ATG- 3'. Gel-purified PCR products were digested with BamH1 and NotI and ligated into the corresponding sites in pcDNA5/FRT/TO. The structure of all constructs was verified by DNA sequence analysis.
###end p 16
###begin title 17
Plasmids
###end title 17
###begin p 18
###xml 90 94 90 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Berger1">[29]</xref>
###xml 96 100 96 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Malim1">[30]</xref>
###xml 286 290 286 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Tokunaga1">[31]</xref>
###xml 349 353 345 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Li2">[32]</xref>
###xml 502 505 494 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 583 587 575 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Fouchier1">[33]</xref>
###xml 662 666 654 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Landau1">[34]</xref>
###xml 4 7 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 29 32 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 106 110 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 223 228 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 296 301 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The HIV-CAT reporter and the CMV-driven Tat plasmid, pcTat have been described previously [29], [30]. The SV40-driven luciferase reporter, pGL3-Control Vector (Promega), was used to control for transfection efficiency. The HIV-1 proviral indicator plasmid, pNL-Luc-HXB was described in [31]. The HIV-1 pNL4-3 plasmid, pSG3DeltaEnv, was described in [32]. pSG3DeltaEnv contains a four nucleotide insertion mutation that encodes a truncated gp120, without disrupting any of the known splicing regulatory cis elements. The plasmid expressing the VSV-G envelope, pHIT/G was described in [33]. The plasmid expressing the AMLV envelope, pSV-A-MLV-env was described in [34].
###end p 18
###begin title 19
Cell culture
###end title 19
###begin p 20
###xml 235 238 217 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tet</italic>
###xml 645 649 619 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Bonano1">[35]</xref>
###xml 181 184 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 394 400 <span type="species:ncbi:9913">bovine</span>
The Flp-In trade mark T- Rextrade mark -293 cell line is a stable, tetracycline-inducible, mammalian expression cell line. It was used here to express shRNAs under the control of a CMV promoter that contained two tandem repeats of the tet operator 2 sequence. T-Rex-293 cells that harbored the pFRT/lacZeo and pcDNA6/TR plasmids were cultured in DMEM (high glucose) supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin and 1% L-glutamine. Zeocin (100 microg/mL) and blasticidin (15 microg/mL) were included to select for cells containing a single integrated FRT site and the Tet repressor plasmid. A GFP-expressing plasmid, Gint [35], was linearized with DraIII and transfected into T-Rex-293 cells using Lipofectamine 2000 (Invitrogen). Genetecin (500 microg/mL) was added to culture media and was changed every three days until a stable, polyclonal population was obtained. These cells were sorted by fluorescence activated cell sorting (FACS) to isolate the population with high GFP expression. shRNAs described above in pcDNA5/FRT/TO and empty vector pcDNA5/FRT/TO were each cotransfected with pOG44 (to express Flp recombinase) into GFP-positive T-Rex -293 cells, and stably transfected cells were selected with hygromycin (200 microg/mL), blasticidin (15 microg/mL), and geneticin (500 microg/mL). Tetracycline-reduced FBS (Hyclone) was used for all cultures that contained a tetracycline-inducible plasmid to minimize basal shRNA expression. Tetracycline concentrations and induction times were optimized for each shRNA expressed to achieve maximal knockdown. Cell viability was assessed at various time pointstime points after shRNA induction using trypan blue exclusion. The dye was added to trypsinized cells to 0.2% (v/v), and viable cells were counted on a hemocytometer. Cell confluency was evaluated at various time points by imaging cells on an Olympus (Melville, NY) IX71 epifluorescence microscope. Images were acquired with an Olympus DP70 digital camera, and images were processed with DP Controller software (Olympus).
###end p 20
###begin p 21
###xml 373 377 373 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Derdeyn1">[36]</xref>
HeLa cells were cultured in DMEM (high glucose) with 10% FBS and 1% penicillin/streptomycin. HeLa cells stably expressing the non-silencing shRNA or Tat-SF1(C) were created by linearizing the plasmids with BstBI and ApaI, respectively, before transfection into HeLa cells using Lipofectamine 2000. Positive transfectants were selected with puromycin. 293T and TZM-bl cells [36] were cultured in DMEM (high glucose) with 10% FBS and 1% penicillin/streptomycin.
###end p 21
###begin title 22
Western blot analysis
###end title 22
###begin p 23
###xml 220 226 <span type="species:ncbi:9986">rabbit</span>
###xml 424 430 <span type="species:ncbi:9986">Rabbit</span>
Protein concentrations of cell lysates were determined by a Bradford assay (Bio-Rad) and 30 microg of protein was separated on SDS-PAGE gels before transferring to PVDF membranes (BioRad). The membranes were probed with rabbit polyclonal antibodies to CCNT1 (AbCam) at a 1:500 dilution, PTB (Intronn, LLC, Durham, NC) at a 1:5000 dilution or antiserum to Tat-SF1 (Research Genetics Inc, Huntsville, AL) at a 1:500 dilution. Rabbit secondary antibody (Amersham) was used at a 1:5000 dilution and proteins were detected with ECL (Amersham) or SuperSignal West Chemiluminescence Substrate (Pierce).
###end p 23
###begin title 24
###xml 33 38 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Pseudotyped virus production and HIV-1 replication assays
###end title 24
###begin p 25
293T cells were plated in 100-mm dishes and cotransfected with 1 microg pHIT/G (for VSV-G envelope production) or 1 microg pSV-A-MLV-env (for AMLV envelope production) and 10 microg pNL-Luc-HXB using the calcium phosphate method. Media was changed the following day and supernatants were passed through a 0.45-microm pore size filter 48 hours post transfection. Viral supernatants not used immediately were frozen at -80degreesC.
###end p 25
###begin p 26
###xml 180 181 176 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 645 650 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
T-Rex-293 cell lines expressing either empty pcDNA5/FRT/TO or a plasmid with an shRNA targeting GFP or Tat-SF1 were induced with 2.5 microg/mL tetracycline for 48 hours. Then, 2x105 cells were plated per well of a 6-well plate, keeping tetracycline present in the media. Cells were imaged in phase contrast and fluorescence before and after infection to confirm equal confluency. 72 hours post induction, media was removed and 2 mL of viral supernatant was added to the cells. HeLa cells stably expressing either the non-silencing shRNA or an shRNA targeting Tat-SF1 were infected in the same manner. Since 293 and HeLa cells do not express the HIV-1 specific CD4 receptor, only VSV-G or AMLV pseudotyped viruses were able to infect the target cells. After 24 or 48 hours, a luciferase assay was performed on the cell lysates. All values were normalized to the protein concentration of the lysate, determined by the BCA Protein Assay (Pierce).
###end p 26
###begin title 27
TZM-bl assays of infectivity
###end title 27
###begin p 28
###xml 260 264 260 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Brass1">[37]</xref>
###xml 506 507 506 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 648 649 644 645 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 763 767 759 763 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT31</sub>
###xml 774 778 770 774 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JRFL</sub>
###xml 788 792 784 788 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IIIB</sub>
###xml 868 872 864 868 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT31</sub>
###xml 909 912 905 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">env</italic>
###xml 966 970 962 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Keele1">[38]</xref>
###xml 994 999 990 995 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NL4-3</sub>
###xml 1006 1010 1002 1006 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT31</sub>
###xml 1087 1090 1083 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">env</italic>
###xml 1138 1143 1134 1139 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NL4-3</sub>
###xml 1167 1175 1163 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nef-hisD</italic>
###xml 1175 1179 1171 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Lu1">[39]</xref>
###xml 1578 1579 1574 1575 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 49 54 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 758 761 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 769 772 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 783 786 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 863 866 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 989 992 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1001 1004 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1101 1108 <span type="species:ncbi:9606">patient</span>
TZM-bl cells were used for replication-competent HIV-1 infection because they express endogenous CXCR4, transgenic CD4 and CCR5, and integrated Tat-dependent beta-galactosidase and luciferase reporter genes. They have also been shown to be susceptible to RNAi [37]. Empty vector, a non-silencing shRNA, or Tat-SF1-targeting shRNAs were co-transfected with a GFP-expressing plasmid into TZM-bl cells using FuGene6 (Roche). Forty-eight hours post-transfection, GFP-positive cells were collected by FACS. 8x103 sorted cells were plated per well in a 96-well plate in DMEM supplemented with DEAE (15 ng/microL). For reverse transcriptase assays, 1.6x104 sorted cells were plated per well in a 12-well plate. Plated cells were infected with replication-competent HIV-1TT31, HIV-1JRFL, or HIV-1IIIB at multiplicities of infections of 0.004, 0.02, or 0.05 respectively. HIV-1TT31 is a chimeric virus composed of the env gene from an early-transmitted primary virus isolate [38] and the genome of HIV-1NL4-3. HIV-1TT31 was constructed by cotransfecting 293T cells with a single-genome-amplified env gene from patient TT31, and the recombinant HIVNL4-3 backbone, pHIVenvBstEIInef-hisD[39]. Supernatants from the transfected cells were harvested 3 days post-transfection and used to generate viral stocks in peripheral blood mononuclear cells. At 3 or 6 days post-infection with replication-competent virus, lysates were prepared for luciferase assays with the Britelite Gene Assay System (PerkinElmer) according to the manufacturer's instructions. Luciferase values were read on a Victor3 (PerkinElmer) reader. Values shown are the means of three independently transfected, FACS sorted, and infected wells. The error bars represent standard error. Lysates from GFP-sorted, uninfected cells were prepared in SDS lysis buffer to analyze levels of Tat-SF1 by western blot both at the time of infection (48 hours after knockdown) and at the end of the experiment.
###end p 28
###begin title 29
Reverse transcriptase assays of infectivity
###end title 29
###begin p 30
###xml 77 81 77 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Willey1">[40]</xref>
###xml 83 87 83 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Chen1">[41]</xref>
###xml 154 158 154 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IIIB</sub>
###xml 429 430 421 422 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 474 479 462 467 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12&#8211;18</sub>
###xml 538 540 522 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 149 152 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Virion-associated reverse transcriptase was measured as described previously [40], [41]. Briefly, cell culture supernatants from cells infected with HIV-1IIIB were harvested by centrifugation for 5 min at 1500 rpm and treated with Triton X-100 at a final concentration of 1%. 10 microL of treated supernatant was added to 40 microl of reaction cocktail containing: 50 mM Tris-HCl pH 7.8, 75 mM KCl, 2 mM Dithiothreital, 5 mM MgCl2, 5 microg/mL Poly A, 0.03 units/mL oligo dT12-18, 0.05% Igepal CA-630, 10 mM EGTA, and 10 microCi/mL dTTP [32P] (MP Biomedical, Solon,OH). Reactions were incubated at 37degreesC for 90 min. 40 microL of the reverse transcription reaction was blotted onto DE 81 membrane (Thermal Scientific, Odessa, TX) using a Schleicher and Schuell Minifold and a vacuum. The blotted membranes were washed briefly with 2x SSC (0.3 M NaCl, 0.03 M Sodium Citrate) at room temperature and exposed to a storage phosphor screen overnight. The screen was scanned with a Typhoon phosphor image, and the data analyzed with ImageQuant 5.2 software (GE Healthcare, Piscataway, NJ).
###end p 30
###begin title 31
Tat transactivation assays
###end title 31
###begin p 32
###xml 1105 1109 1085 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Neumann1">[42]</xref>
###xml 551 554 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 569 573 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 676 679 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
HeLa cells were seeded in a 24-well plate before transient transfection with 0.4 microg of either empty pSuper plasmid, a non-silencing shRNA , or Tat-SF1(A) and Tat-SF1(B) in combination using Lipofectamine 2000. After 24 hours of knockdown, cells were passaged to a 6-well plate before transient transfection of reporter plasmids. T-Rex-293 cells were induced with 2.5 microg/mL tetracycline for 48 hrs and seeded in a 6-well plate before transient transfection of reporter plasmids. The calcium phosphate method was used to transfect 0.5 microg of HIV-CAT, 50 ng of SV40-LUC as an internal control for transfection efficiency, and the indicated amount of either pcTat or a CMV-driven empty vector. Twenty-four hours later, lysates were prepared using 500 microL of Cell Culture Lysis Reagent (Promega). Luciferase assays were performed with 40 microL of lysate using a Luciferase Assay Kit (Promega) according to the manufacturer's instructions. Readings were obtained using a Lumat LB 9507 Luminometer (EG&G Berthold). CAT assays were performed using the diffusion method on the same volume of lysate [42]. Both reporter gene assays were background corrected with values obtained from lysis buffer alone. All CAT values were normalized to luciferase values.
###end p 32
###begin title 33
Northern blot analysis
###end title 33
###begin p 34
###xml 107 108 103 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1067 1068 1045 1046 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1070 1071 1048 1049 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1240 1244 1212 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Lin1">[43]</xref>
###xml 1258 1260 1226 1228 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1343 1344 1311 1312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 1131 1136 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1217 1222 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1901 1906 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2076 2081 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
T-Rex-293 cells were induced with 2.5 microg/mL of tetracycline for 48 hours, plated in 6-well plates (4x105 cells/well), and after an additional 24 hours, transiently transfected with 1 microg of pSG3DeltaEnv by the calcium phosphate method. Each shRNA-expressing cell line was transfected in triplicate and tetracycline was present in the media at all times. Media was replaced the day following transfection, and 48 hours post-transfection, cells were washed and total RNA was extracted with TRIzol (Invitrogen). 4 microg of total RNA was subjected to a glyoxylation reaction for 1 hour at 55degreesC. RNAs were immediately chilled for 10 minutes on ice before separation on a 0.8% agarose gel. RNA was transferred overnight to BrightStar-Plus positively charged nylon membrane (Ambion) by capillary action in 10x SSC. After crosslinking the membrane in a UV Stratalinker 2400 (Stratagene), transfer efficiency was assessed by staining the membrane with methylene blue and the agarose gel with ethidium bromide. Membranes were prehybridized for 2 hours in 0.5 M Na3PO4, pH 7.2, 7% (w/v) SDS, 1 mM EDTA, pH 7.0 at 68degreesC. An HIV-1 LTR radiolabelled probe was generated from a 25 ng KpnI-HindIII fragment of the HIV-1 LTR described in [43] using [alpha-32P]dCTP and the Random Primers DNA Labeling Kit (Invitrogen). Denatured probe (>1x107 cpm) was added to hybridization solution and incubated with the membrane for at least 1 hour at 68degreesC. Membranes were washed once at room temperature in 1x SSC+0.1% SDS, then three times at 68degreesC in 0.5x SSC+0.1% SDS, followed by overnight exposure to film with an intensifying screen at -80degreesC or a phosphor screen. Membranes were stripped with boiling 0.5% SDS and reprobed with a random primed GAPDH PCR product. Northern blots were quantified with ImageQuant by first background correcting each band. The proportion of each of the three HIV-1 RNA classes in cells depleted of Tat-SF1 was expressed relative to the proportion of the same RNA class in cells treated with the control shRNA. Quantification of total HIV-1 transcripts levels was achieved by adding the values of the 9 kb, 4 kb, and 2 kb signals and normalizing to the GAPDH signal. Statistical significance was determined using a paired Student's t test, and significance was set at p<0.05.
###end p 34
###begin title 35
###xml 53 58 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Reverse transcription and real-time PCR detection of HIV-1 transcripts
###end title 35
###begin p 36
###xml 409 413 409 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Overman1">[44]</xref>
###xml 1384 1388 1340 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Arrigo1">[45]</xref>
###xml 1431 1436 1387 1392 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NL4-3</sub>
###xml 336 341 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1192 1197 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1288 1293 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1468 1473 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Total cellular RNA was isolated using TRIzol per the manufacturer's protocol. RNA samples were then subjected to two rounds of DNase digestion to remove residual DNA using DNA-free (Ambion). To verify the removal of DNA, each RNA sample was tested in triplicate by real-time PCR using SYBR Green PCR Master Mix (Applied Biosystems) and HIV-1 LTR specific primers (HIVshortF and HIVshortR) described elsewhere [44]. Real-time reactions were performed in an ABI 7500 Real-time PCR System (Applied Biosystems) with the following cycling profile: one cycle of 50degreesC for 5 min, one cycle of 95degreesC for 10 min, 40 cycles of 95degreesC for 15 s and 60degreesC for 1 min. Reverse transcription was performed on 300 ng of each RNA sample for 1 h at 37degreesC using M-MLV Reverse Transcriptase (Invitrogen), 6 microg of random hexamer primers (Invitrogen), 0.67 mM dNTPs (Invitrogen), 40 U RNAse Out (Invitrogen), and First Strand Buffer (Invitrogen) in a 45 microL final reaction volume. The enzyme was then inactivated by incubating the reactions at 70degreesC for 15 min. The resulting cDNAs were tested in real-time PCR reactions to determine the absolute quantity of total and unspliced HIV-1 transcripts using the PCR master mix and cycling profile described above. Total initiated HIV-1 transcripts were amplified using primers HIVshortF and HIVshortR. PCR primers LA8 and LA9 [45] were modified to match the sequence of HIVNL4-3, and used to amplify unspliced HIV-1 transcripts. Dissociation curves were performed on all PCR reactions to determine the specificity of each PCR reaction. The absolute quantification data was analyzed using Sequence Detection Software v1.2.2 (Applied Biosystems).
###end p 36
###begin title 37
Results
###end title 37
###begin title 38
Tat-SF1 depletion does not affect T-Rex-293 cell viability
###end title 38
###begin p 39
###xml 58 65 58 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1055 1064 1055 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g001">Figure 1A</xref>
###xml 1262 1271 1262 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g001">Figure 1A</xref>
###xml 1430 1439 1430 1439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g001">Figure 1B</xref>
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To test the importance of Tat-SF1 in the HIV-1 life cycle in vivo, we used RNAi to specifically silence its expression. Four T-Rex-293 cell lines were constructed containing four unique shRNAs that targeted Tat-SF1, which were expressed from tetracycline-inducible promoters (see Materials and Methods). This system minimized continuous expression of the shRNAs until tetracycline was added to the media, thus reducing selection based on shRNA expression. All of the cell lines were tested for shRNA-mediated Tat-SF1 depletion, and the two most efficient, Tat-SF1(A) and Tat-SF1(B), were used in all subsequent experiments. In addition, two control cell lines were made that stably integrated either an empty vector (no shRNA) or an shRNA targeting GFP. Tetracycline concentration and induction time were optimized to achieve the maximum level of knockdown. Analysis of cell lysates from induced cells shows that both cell lines that contain an shRNA targeting Tat-SF1 have significantly lower Tat-SF1 protein levels compared to the empty vector control (Figure 1A). The knockdown of Tat-SF1 by either shRNA did not affect the levels of CCNT1, a direct binding partner of Tat-SF1, or the polypyrimidine tract binding protein (PTB), an unrelated splicing factor (Figure 1A). Flow cytometry demonstrated that the cell line containing an shRNA targeting GFP produced an active shRNA, as GFP levels were reduced by approximately 50% (Figure 1B) while Tat-SF1 levels were unchanged (data not shown). Tetracycline induction for 72 hours was chosen for the functional assays, although 96 hours also showed persistent knockdown.
###end p 39
###begin title 40
Tat-SF1 depletion does not affect T-Rex-293 cell viability.
###end title 40
###begin p 41
(A) Analysis of Tat-SF1 knockdown by Western blot. T-Rex-293 cells were induced with tetracycline and lysates were made at the time points indicated. Equal protein amounts were loaded for Western blot analysis with antibodies against Tat-SF1, CCNT1 and PTB. Lanes 1-3 are from cells that express an empty vector control and lanes 4-9 are from cells that express one of two unique shRNAs targeting Tat-SF1. (B) Analysis of GFP knockdown by flow cytometry. T-Rex-293 cells were induced with tetracycline for 72 hours, and resuspended cells were fixed with formaldehyde for flow cytometry analysis. The bar graph quantifies the mean GFP level of each sample. (C) Analysis of cell viability by trypan blue exclusion. Equivalent numbers of T-Rex-293 cells (expressing either an empty vector control, an shRNA targeting GFP, or one of two shRNAs targeting Tat-SF1) were induced with tetracycline for the times indicated. Viable cells per mL are reported as a means of three independent experiments. Error bars represent standard error. (D) Analysis of cell viability by fluorescence microscopy. Equal numbers of T-Rex-293 cells were induced with tetracycline for the times indicated and imaged with fluorescence microscopy.
###end p 41
###begin p 42
###xml 230 239 230 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g001">Figure 1C</xref>
###xml 717 726 717 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g001">Figure 1D</xref>
###xml 896 899 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We first sought to evaluate the effect of Tat-SF1 knockdown on T-Rex-293 cell viability. Trypan blue exclusion was used to quantify viability in the control and knockdown cells at 24, 48, and 72 hours post-tetracycline induction. Figure 1C shows the average number of viable cells per mL in each cell line. The number of viable cells per mL in the Tat-SF1 knockdown cell lines was not significantly different from the control cells at the end of the experiment. The Tat-SF1(B) shRNA shows slightly lower cell viability initially, however, this difference is not significant at later time points. The density of the Tat-SF1 knockdown cells was also indistinguishable from that of the control cells at each time point (Figure 1D). These data indicate that Tat-SF1 depletion did not affect T-Rex-293 cell viability, and therefore, we proceeded to assay the role of Tat-SF1 as a cellular cofactor of HIV.
###end p 42
###begin title 43
###xml 27 32 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tat-SF1 depletion inhibits HIV-1 infectivity
###end title 43
###begin p 44
###xml 55 62 55 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1145 1154 1145 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g002">Figure 2A</xref>
###xml 135 140 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 247 273 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
###xml 438 443 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1022 1027 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1223 1228 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
If Tat-SF1 was indeed required for Tat transactivation in vivo, then RNAi-mediated depletion of Tat-SF1 should decrease the ability of HIV-1 to replicate. To test this hypothesis, control and Tat-SF1 knockdown T-Rex-293 cells were infected with a vesicular stomatitis virus G-protein (VSV-G) pseudotyped virus in a single-round replication assay. Although this pseudotyped virus does not produce infectious progeny due to its lack of the HIV-1 envelope, we use the term replication here to refer to the reproduction of viral genomes. Serial dilutions of the viral stock were added to cells and lysates were assayed for luciferase activity, which indicates LTR-dependent transcription, processing, and expression. To control for any differences in cell number between control and knockdown cell lines, cells were imaged before and after infection to ensure equal confluency, and luciferase values were normalized to the protein content of the lysate. Surprisingly, both of the Tat-SF1 knockdown cell lines showed levels of HIV-1 replication that were no different than those in the empty vector and GFP control cells after 24 hours of infection (Figure 2A). This remained true even with a 1:100 dilution of the viral stock. HIV-1 replication was also unaffected by Tat-SF1 knockdown after 48 hours of infection (data not shown).
###end p 44
###begin title 45
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tat-SF1 depletion does not affect pseudotyped HIV-1 replication.
###end title 45
###begin p 46
(A) VSV-G replication assay. Serial dilutions of pseudotyped virus (VSV-G envelope) were used in a single-round replication assay with T-Rex-293 cells expressing an empty vector, an shRNA targeting GFP, or shRNAs targeting Tat-SF1. A western blot confirming knockdown is shown below the chart. Luciferase values of the cell lysates were read after 24 hours. Luciferase values were background corrected and normalized to protein content. (B) AMLV replication assay. An AMLV-pseudotyped virus was used in the same type of experiment described in (A) except that lysates were harvested after 48 hours. Values reported are the means of triplicate wells. Error bars represent standard error. The western blot in (A) also corresponds to the cells used in this experiment. (C) VSV-G-replication assay. Pseudotyped virus was used on HeLa cells stably expressing a non-silencing shRNA or a third shRNA targeting Tat-SF1. Luciferase values of the cell lysates were read after 24 hours. Luciferase values were background corrected and normalized to protein content. Values are reported as the means of triplicate wells. Error bars represent standard error.
###end p 46
###begin p 47
###xml 383 392 383 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g002">Figure 2B</xref>
###xml 340 345 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
It was possible that the VSV-G pseudotyped virus was infecting the cells so efficiently that any deficiency due to Tat-SF1 depletion was being masked. To address this possibility, we also assessed replication using an AMLV-pseudotyped virus, which infects target cells with a lower efficiency. Again, there was no significant difference in HIV-1 replication after Tat-SF1 knockdown (Figure 2B).
###end p 47
###begin p 48
###xml 362 371 362 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g002">Figure 2C</xref>
###xml 563 569 563 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 673 677 673 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Brass1">[37]</xref>
###xml 442 447 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 619 624 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Earlier studies of Tat-SF1 function were performed in HeLa cells, so we next tested our hypothesis by infecting HeLa cells that stably expressed a third shRNA targeting Tat-SF1, Tat-SF1(C). Tat-SF1 depletion did not significantly affect cell viability in HeLa cells (data not shown). Again, replication in Tat-SF1 depleted cells was comparable to control cells (Figure 2C). This led us to conclude that either Tat-SF1 had a minimal effect on HIV-1 replication, or it affected a step not interrogated by the experiments with these pseudotyped viruses. Since Brass et al. identified Tat-SF1 as a host factor required for HIV-1 propagation using a replication-competent virus [37], we favored the latter explanation.
###end p 48
###begin p 49
###xml 375 379 375 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Brass1">[37]</xref>
###xml 493 497 493 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Derdeyn1">[36]</xref>
###xml 499 503 499 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Wei2">[46]</xref>
###xml 847 851 847 851 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT31</sub>
###xml 860 864 860 864 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JRFL</sub>
###xml 871 875 871 875 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JRFL</sub>
###xml 921 925 921 925 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT31</sub>
###xml 988 992 988 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Keele1">[38]</xref>
###xml 1190 1206 1190 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g003">Figures 3A and B</xref>
###xml 413 418 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 444 449 <span type="species:ncbi:9606">human</span>
###xml 827 832 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 842 845 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 855 858 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 866 869 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 916 919 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1112 1117 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1258 1263 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In order to test if Tat-SF1 played a role in any step of the viral life cycle, we decided to assess the effect of Tat-SF1 depletion with a replication-competent virus. TZM-bl cells were used because they express CXCR4, CD4 and CCR5, and also contain integrated Tat-dependent beta-galactosidase and luciferase reporter genes. These cells are amenable to treatment with siRNAs [37] and have equal susceptibility to HIV-1 infection as compared to human peripheral blood mononuclear cells (PBMCs) [36], [46]. TZM-bl cells were transiently transfected with an empty vector, a non-silencing shRNA, or Tat-SF1 specific shRNAs. These cells were cotransfected with a GFP expressing plasmid to sort GFP-positive cells. GFP-positive transfectants were plated in 96-well plates and infected with one of two different replication-competent HIV-1 strains, HIV-1TT31 or HIV-1JRFL. HIV-1JRFL is a laboratory adapted strain, whereas HIV-1TT31 encodes an envelope from an early-transmitted primary isolate [38]. After 3 days of infection, a luciferase assay was performed on the cell lysates. Upon Tat-SF1 depletion, the level of HIV-1 infection decreased approximately 3-fold compared to the control cells (Figures 3A and B). The decrease in infectivity was similar for both HIV-1 strains tested. A comparable decrease in infectivity after 6 days of infection was also observed (data not shown). Lysates from uninfected cells showed persistent knockdown of Tat-SF1 throughout the length of the experiment (data not shown).
###end p 49
###begin title 50
###xml 27 32 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tat-SF1 depletion inhibits HIV-1 infectivity.
###end title 50
###begin p 51
###xml 28 32 28 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT31</sub>
###xml 62 66 62 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT31</sub>
###xml 331 343 331 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g003">Figures 3A&#8211;D</xref>
###xml 548 552 548 552 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JRFL</sub>
###xml 581 585 581 585 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JRFL</sub>
###xml 672 676 672 676 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IIIB</sub>
###xml 705 709 705 709 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IIIB</sub>
###xml 23 26 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 57 60 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 543 546 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 576 579 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 667 670 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 700 703 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(A) TZM-bl assay using HIV-1TT31 . Replication-competent HIV-1TT31 was used to infect TZM-bl cells that were transiently transfected with either an empty vector, a non-silencing shRNA control, or shRNAs targeting Tat-SF1. A western blot confirming knockdown is shown below the chart. This western blot corresponds to cells used in Figures 3A-D. Luciferase values of the cell lysates were read 3 days after infection. Luciferase values were reported as the means of triplicate wells. Error bars represent standard error. (B) TZM-bl assay using HIV-1JRFL. Replication-competent HIV-1JRFL was used in the same type of experiment described in (A). (C) TZM-bl assay using HIV-1IIIB. Replication-competent HIV-1IIIB was used in the same type of experiment described in (A) and (B), except that cell lysates were read 6 days after infection. (D) Reverse transcriptase assay. Supernatants from infected cells in (C) were measured for reverse transcriptase activity 3 and 6 days after infection. Values from the phosphor screen image were reported as the means of triplicate wells. Error bars represent standard error.
###end p 51
###begin p 52
###xml 86 90 86 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IIIB</sub>
###xml 421 430 421 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g003">Figure 3C</xref>
###xml 707 716 707 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g003">Figure 3D</xref>
###xml 81 84 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 390 395 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
As an independent, more direct measurement of viral infectivity, a third strain, HIV-1IIIB, was used to infect control and Tat-SF1 knockdown TZM-bl cells, and the viral supernatants from these cells were assayed for reverse transcriptase activity. Luciferase readings from the infected cell lysates recapitulated the decrease in infectivity upon Tat-SF1 depletion that was seen for the two HIV-1 strains used previously (Figure 3C). After 3 days of infection, both control and Tat-SF1 knockdown cells produced background levels of reverse transcriptase. After 6 days of infection, the most efficient knockdown cells, Tat-SF1(B), showed an inability to produce reverse transcriptase above background levels (Figure 3D).
###end p 52
###begin p 53
###xml 97 102 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Together, these data indicated that Tat-SF1 plays a positive role in regulating the lifecycle of HIV-1 at a step not interrogated by pseudotyped viruses. This conclusion was not easily reconciled with an effect on Tat transactivation.
###end p 53
###begin title 54
###xml 54 61 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Tat-SF1 depletion does not affect Tat transactivation in vivo
###end title 54
###begin p 55
###xml 37 45 37 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 119 126 119 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 490 494 490 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Malim1">[30]</xref>
###xml 631 640 631 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g004">Figure 4A</xref>
###xml 753 762 753 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g004">Figure 4B</xref>
###xml 767 774 767 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005710-t001">Table 1</xref>
###xml 1057 1066 1057 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g004">Figure 4C</xref>
###xml 1071 1078 1071 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005710-t002">Table 2</xref>
###xml 1127 1135 1127 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1233 1240 1233 1240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 330 335 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1223 1228 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Although Tat-SF1 has been implicated in vitro as a cofactor for the viral protein Tat, this had yet to be demonstrated in vivo. To examine Tat transactivation when Tat-SF1 was depleted, control and Tat-SF1 knockdown HeLa cell lines were transfected with a chloramphenicol acetyltransferase (CAT) reporter under the control of the HIV-1 LTR. This plasmid, along with an internal luciferase control for transfection efficiency, was cotransfected with either the Tat-expressing plasmid, pcTat [30], or an empty vector. The amount of pcTat transfected was experimentally determined so that Tat transactivation was in the linear range (Figure 4A). As expected, Tat stimulated transcription of the CAT reporter gene by approximately 40-fold in control cells (Figure 4B and Table 1). Surprisingly, similar levels of Tat transactivation were seen when Tat-SF1 was depleted. Furthermore, basal transcription of the LTR (in the absence of Tat) was unaffected by RNAi-mediated depletion of Tat-SF1. In addition, the same results were recapitulated in T-Rex-293 cells (Figure 4C and Table 2). These findings indicate that, contrary to the in vitro results, Tat-SF1 depletion did not affect basal or Tat-mediated transactivation of the HIV-1 LTR in vivo.
###end p 55
###begin title 56
###xml 90 97 90 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tat-SF1 depletion does not affect basal or Tat-dependent transcription from the HIV-1 LTR in vivo.
###end title 56
###begin p 57
###xml 885 892 885 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005710-t001">Table 1</xref>
###xml 1417 1424 1417 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005710-t002">Table 2</xref>
###xml 88 93 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 115 119 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
(A) Tat titration. HeLa cells were cotransfected with the indicated amount of pcTat, an HIV-1 CAT reporter, and an SV40-Luciferase reporter. Lysates were subjected to a CAT assay and normalized with values obtained from a luciferase assay 24 hours after cotransfection. All CAT and Luciferase values were background corrected. Values shown are the means of duplicate transfections. (B) Tat transactivation assay in HeLa cells. HeLa cells were transiently transfected with either an empty vector, a non-silencing shRNA, or two shRNAs targeting Tat-SF1. A western blot confirming knockdown is shown below the chart. Cells were cotransfected with the same reporters as in (A) plus 0.3 ng pcTat or an empty vector. All CAT and Luciferase values were background corrected, and CAT was normalized to Luciferase. Values shown are the means of duplicate transfections. Raw values are shown in Table 1, Exp. 1. (C) Tat transactivation in T-Rex-293 cells. T-Rex-293 cells harboring either an empty vector control, an shRNA targeting GFP, or one of two shRNAs targeting Tat-SF1 were induced with tetracycline for 48 hours. A western blot confirming knockdown is shown below the chart. Cells were cotransfected with the same reporters as in (A) and (B). All CAT and Luciferase values were background corrected, and CAT was normalized to Luciferase. Values shown are the means of triplicate transfections. Raw values are shown in Table 2. Error bars represent standard error.
###end p 57
###begin title 58
###xml 88 89 88 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="nt101">*</xref>
###xml 55 60 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Effect of Tat-SF1 depletion on basal and Tat-dependent HIV-1 transcription in HeLa cells*.
###end title 58
###begin p 59
###xml 131 140 131 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g004">Figure 4B</xref>
Values shown are the means of duplicate wells for 3 independent experiments. Row 1 is calculated from the same experiment shown in Figure 4B. CAT activity was the value of the slope of the linear function obtained by plotting cpm of acetylated chloramphenicol versus time. Luciferase activity of the same sample was measured with a luminometer. For both reporter assays, background values obtained from lysis buffer alone were subtracted from each sample.
###end p 59
###begin title 60
###xml 93 94 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="nt102">*</xref>
###xml 55 60 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Effect of Tat-SF1 depletion on basal and Tat-dependent HIV-1 transcription in T-Rex-293 cells*.
###end title 60
###begin p 61
###xml 93 102 93 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g004">Figure 4C</xref>
Values shown are the means of triplicate wells, calculated from the same experiment shown in Figure 4C. CAT activity was the value of the slope of the linear function obtained by plotting cpm of acetylated chloramphenicol versus time. Luciferase activity of the same sample was measured with a luminometer. For both reporter assays, background values obtained from lysis buffer alone were subtracted from each sample.
###end p 61
###begin title 62
###xml 32 37 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tat-SF1 maintains the ratios of HIV-1 RNAs
###end title 62
###begin p 63
###xml 829 838 789 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g005">Figure 5A</xref>
###xml 841 850 801 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g005">Figure 5B</xref>
###xml 1356 1365 1312 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g005">Figure 5C</xref>
###xml 53 58 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 168 173 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 331 336 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 557 562 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1146 1151 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Although Tat-SF1 depletion resulted in a decrease in HIV-1 infectivity, it did not affect Tat transactivation. Rather than having a role in transcription elongation of HIV-1 RNA, it seemed possible that Tat-SF1 could post-transcriptionally regulate viral gene expression. To test this hypothesis, we used Northern blots to analyze HIV-1 RNAs in control and knockdown cells. The pSG3DeltaEnv plasmid was transfected into GFP control and Tat-SF1 knockdown T-Rex-293 cell lines, and total RNA was harvested 48 hours later. Hybridization was performed using an HIV-1 LTR-specific radiolabeled probe that detects all three classes of viral RNAs: unspliced (approximately9 kb), singly spliced (approximately4 kb), and fully spliced (approximately2 kb). A western blot of T-Rex-293 cell lysates confirms efficient knockdown of Tat-SF1 (Figure 5A). Figure 5B shows the results of a representative Northern blot probing RNA from GFP control and Tat-SF1 knockdown cell lines 48 hours after transfection with the pSG3DeltaEnv plasmid. In the mock transfected lane, no viral pre-mRNA signal is detected, indicating that the bands seen in the other lanes are HIV-1-specific. Quantification of each RNA class demonstrates that intron-containing unspliced and singly spliced transcripts were elevated and fully spliced transcripts were reduced when Tat-SF1 was depleted (Figure 5C). This corresponds to an unspliced/fully spliced ratio of approximately0.7 in GFP control cells and approximately1.6 in Tat-SF1 depleted cells. Similar changes in ratios were observed when another viral plasmid, pNL-Luc-HXB, was transfected into Tat-SF1 depleted T-Rex-293 cells (data not shown). These data further suggest a post-transcriptional role for Tat-SF1.
###end p 63
###begin title 64
###xml 54 59 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tat-SF1 maintains the levels of unspliced and spliced HIV-1 RNAs.
###end title 64
###begin p 65
###xml 112 117 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 346 351 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 751 756 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1117 1122 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1448 1453 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1633 1638 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1717 1722 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(A) Western blot analysis confirming knockdown in T-Rex-293 cells. (B) Representative Northern blot analysis of HIV-1 RNA classes. T-Rex-293 cells were transfected with pSG3DeltaEnv 72 hours after tetracycline induction. At 48 hours post-transfection, total RNA was isolated for electrophoresis and Northern blotting. A DNA probe specific to the HIV-1 LTR detected the approximately9 kb unspliced, approximately4 kb singly spliced, and approximately2 kb fully spliced RNAs. Lane 1 contains RNA from mock-transfected GFP control cells, lane 2 from transfected GFP control cells, and lanes 3 and 4 from transfected Tat-SF1 shRNA cells. The lower panel shows the same membrane, stripped and reprobed for GAPDH. (C) Tat-SF1 depletion alters the levels of HIV-1 RNA classes. Values are reported as the mean proportion of each RNA class, relative to the GFP control cells from three independent Northern blot experiments. Error bars represent standard error. Statistically significant differences between GFP control and Tat-SF1 knockdown conditions are indicated with asterisks. (D) Tat-SF1 depletion does not alter total HIV-1 RNA levels. Levels of the 3 RNA classes quantified from triplicate Northern blots were totaled and normalized to GAPDH levels. Values are reported as the means relative to the GFP control cells from three independent experiments. Error bars represent standard error. (E) Tat-SF1 depletion results in an increase in unspliced HIV-1 transcripts. qRT-PCR was performed on the same RNA samples used for Northern blot experiments. The medians of triplicate amplifications (both unspliced products and all initiated HIV-1 transcripts) were calculated and means of unspliced transcripts/all initiated HIV-1 transcripts ratios from triplicate samples are reported. Error bars represent standard error.
###end p 65
###begin p 66
###xml 313 322 313 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g005">Figure 5D</xref>
###xml 43 48 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 209 214 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To test whether or not the total amount of HIV-1 transcripts was altered by Tat-SF1 depletion, total viral RNAs were quantified from triplicate Northern blot experiments and normalized to GAPDH. Indeed, total HIV-1 RNA levels were not significantly different between the control and Tat-SF1 knockdown cell lines (Figure 5D).
###end p 66
###begin p 67
###xml 247 251 247 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Exline1">[47]</xref>
###xml 681 685 681 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Exline1">[47]</xref>
###xml 1000 1009 1000 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005710-g005">Figure 5E</xref>
###xml 1169 1176 1169 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1158 1163 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
As an independent test of a change in the splicing pattern, the same RNAs used in the Northern blot experiments were analyzed by qRT-PCR. We attempted the specific amplification of the 9 kb, 4 kb and 2 kb classes using previously published oligos [47]. Nonetheless, separation the PCR products on an acrylamide gel revealed that, although the 9 kb primers produced one distinct band, the 4 kb and 2 kb primers produced multiple amplicons larger than the expected one (likely including unspliced RNAs). In addition, the qPCR melting curves indicated more than one product for the 4 kb amplification. In fact, careful inspection of the design of the oligos used in a previous report [47] suggests that the reported RNA-class specificity would be exceedingly difficult to achieve. Nevertheless, the quantification of the unspliced RNAs over all initiated transcripts confirmed that there was an increase in the 9 kb, unspliced transcripts upon Tat-SF1 knockdown, in concordance with the Northern blots (Figure 5E). This change in the viral splicing pattern suggests that Tat-SF1 plays a post-transcriptional role in regulating the ratio of unspliced to spliced HIV-1 RNAs in vivo.
###end p 67
###begin title 68
Discussion
###end title 68
###begin p 69
###xml 253 260 253 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 311 315 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Zhou2">[16]</xref>
###xml 317 321 317 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Kim1">[22]</xref>
###xml 855 859 855 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Sune1">[17]</xref>
###xml 72 77 <span type="species:ncbi:9606">human</span>
###xml 109 114 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 243 248 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 982 987 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The results presented here shed new light on the mechanism by which the human protein, Tat-SF1, functions in HIV-1 replication. The first important conclusion was that Tat-SF1 was not required for basal or Tat-dependent transcription from the HIV-1 LTR in vivo. This contradicts previously reported conclusions [16], [22]; however, careful reevaluation of the published data suggests concerns about these earlier inferences. First, as part of a multiprotein complex, immunodepletion of Tat-SF1 from nuclear extract may have resulted in co-depletion of other proteins essential for Tat transactivation, most notably, cyclin T1, which directly binds Tat-SF1. As a subunit of P-TEFb, co-depletion of cyclin T1 could certainly affect levels of transcription. Equally, RNAi-mediated depletion of CA150, which we previously hypothesized would be a Tat cofactor [17] and which is also known to interact with P-TEFb, did not show any effect on basal or Tat-dependent transcription from the HIV-1 LTR (data not shown). In light of these RNAi-mediated depletion experiments, it seems very possible that the identification of both Tat-SF1 and CA150 as Tat cofactors from Tat-affinity column experiments could be explained by their association with P-TEFb.
###end p 69
###begin p 70
###xml 116 120 116 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Zhou2">[16]</xref>
###xml 315 319 315 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Kim1">[22]</xref>
###xml 486 493 486 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 524 528 524 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Bres1">[48]</xref>
###xml 765 769 765 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Zhou4">[49]</xref>
###xml 428 433 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 869 874 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A previous report on Tat-SF1 function showed a small increase in Tat transactivation when Tat-SF1 was overexpressed [16]. As described earlier, this change was primarily due to a decrease in basal transcription, however, even this effect was not reproduced using a different promoter to drive expression of Tat-SF1 [22]. Finally, chromatin immunoprecipitation (ChIP) data indicated that Tat-SF1 was not present at an integrated HIV-1 LTR-driven reporter gene during Tat transactivation in vivo, while RNAPII and P-TEFb were [48]. This finding is difficult to reconcile with Tat-SF1 being a required Tat cofactor. Nonetheless, when a cell line harboring integrated proviral DNA was utilized for ChIP experiments, Tat-SF1 was detected at the promoter-proximal region [49]. In light of our data, we propose that the presence of viral splice sites or other elements in the HIV-1 transcripts explains the recruitment of Tat-SF1 to the proviral locus.
###end p 70
###begin p 71
###xml 282 286 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Kim1">[22]</xref>
###xml 357 361 357 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-WuBaer1">[20]</xref>
###xml 382 386 382 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Ping1">[50]</xref>
###xml 490 495 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
An alternative explanation for the different conclusions drawn from previous overexpression and our knockdown studies is that lack of functioning Tat-SF1 can be compensated by another cellular protein. SPT5 has also been reported to stimulate Tat transactivation when overexpressed [22] and inhibits transactivation when immunodepleted from nuclear extract [20] or depleted by RNAi [50]. CA150 did not compensate for Tat-SF1 depletion, as a double knockdown of both proteins did not affect HIV-1 transcription (data not shown). Our findings do not eliminate the possibility that Tat-SF1 plays some role in Tat transactivation, although it is not absolutely required. A similar caveat, which can be leveled against all silencing experiments, is that a knockdown is not tantamount to a knockout, and the remaining level of the silenced gene product is sufficient for activity. Nonetheless, depletion of Tat-SF1 did result in the reduced viral replication and altered ratios of viral transcripts, so the preponderance of the evidence strongly suggests that Tat-SF1 is not a required Tat stimulatory factor.
###end p 71
###begin p 72
###xml 347 351 347 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Sonza1">[51]</xref>
###xml 353 357 353 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Purcell1">[52]</xref>
###xml 359 363 359 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Gorry1">[53]</xref>
###xml 185 188 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Another important and novel finding presented here is that Tat-SF1 depletion increased the ratio of unspliced to spliced viral transcripts. It should be noted that splicing patterns of HIV transcripts among different cell lines are highly uniform, suggesting that the tight regulation of these transcript ratios is crucial for the viral lifecycle [51], [52], [53].
###end p 72
###begin p 73
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 295 300 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Careful investigation of the changes in HIV-1 spliced ratios over time showed that accumulation of unspliced and singly spliced RNAs and reduction of fully spliced RNAs did not occur until 48 hours post-transfection (data not shown). These data highlight the importance of timing when analyzing HIV-1 spliced RNAs. Thus, we have focused our efforts for determining Tat-SF1's role in maintaining RNA ratios to later time points.
###end p 73
###begin p 74
###xml 763 767 763 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Yan1">[27]</xref>
###xml 1079 1085 1079 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1510 1514 1510 1514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Brass1">[37]</xref>
###xml 1516 1520 1516 1520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Konig1">[54]</xref>
###xml 1522 1526 1522 1526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Zhou5">[55]</xref>
###xml 1581 1587 1581 1587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1598 1604 1598 1604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1802 1807 1802 1807 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 2315 2319 2315 2319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Naito1">[56]</xref>
###xml 145 150 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 209 214 <span type="species:ncbi:4932">yeast</span>
###xml 262 267 <span type="species:ncbi:9606">human</span>
###xml 694 699 <span type="species:ncbi:9606">human</span>
###xml 803 808 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 998 1003 <span type="species:ncbi:9606">human</span>
###xml 1306 1309 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1397 1402 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1480 1483 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2365 2370 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2690 2695 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
While an effect on transcript ratios can be explained by several different mechanisms, we propose that Tat-SF1 regulates alternative splicing of HIV-1 RNAs. This is consistent with previous data regarding the yeast protein CUS2, which is structurally similar to human Tat-SF1. Both proteins contain two RRMs in their N-terminus, but Tat-SF1 has a large acidic C-terminus that is absent in CUS2. The first RRMs of these proteins are 37% identical and 59% similar. The second RRMs are 30% identical and 56% similar. CUS2 associates with U2 snRNA in splicing extracts and co-immunoprecipitates PRP11, which is a subunit of SF3a. When anti-Tat-SF1 antibodies were used for immunoprecipitation, the human homologue of PRP11, SF3a66(SAP62), was also immunoprecipitated [27]. An effect of Tat-SF1 depletion on HIV-1 RNA ratios is also consistent with recent unpublished data from our laboratory that demonstrate that Tat-SF1 depletion changes the relative levels many alternatively spliced transcripts in human cells without affecting the total amount of these transcripts (H.B. Miller et al., unpublished results). An effect on splicing could be direct, as proposed for CUS2. Thus, Tat-SF1 could help in the folding and activity of splicing factors such as U2 snRNAs, but it could also rework the folding of the HIV transcripts leading to efficient splicing. Tat-SF1 may also have an indirect effect on HIV-1 pre-mRNA splicing by regulating the processing of transcripts encoding other HIV dependency factors (HDFs) [37], [54], [55]. In fact, we analyzed the HDFs published by the Brass et al. and Konig et al. screens and found approximately 2-fold enrichment over chance alone in genes that also had evidence of Tat-SF1-regulated alternative splicing (p-values of 0.02 and 0.05, respectively) (H.B. Miller et al, unpublished results). Tat-SF1 could also be involved in virion packaging. The decrease in infectivity in Tat-SF1 depleted cells could be explained if Tat-SF1 was a chaperone protein, helping fold the viral pre-mRNA genome into productive virions. Such a role in viral RNA packaging would be consistent with Tat-SF1's role in influenza virus replication. Tat-SF1 was identified as a stimulatory host factor, possibly aiding in the formation of RNA-nucleoprotein complexes by acting as a molecular chaperone [56]. It remains to be seen whether Tat-SF1 binds HIV-1 pre-mRNA and helps package viral genomes into virions. An increase in the unspliced RNA upon Tat-SF1 knockdown could also be explained by Tat-SF1 having a role in RNA export from the nucleus, although this has not yet been tested. Additionally, Tat-SF1 may play a role in regulating the levels of unspliced and spliced HIV-1 RNAs by affecting their stability. The virus may rely on Tat-SF1 to destabilize unspliced RNAs in order to maintain an optimal ratio of unspliced and spliced RNAs.
###end p 74
###begin p 75
###xml 149 153 149 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Misse1">[57]</xref>
###xml 193 197 193 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Simmons1">[58]</xref>
###xml 371 375 371 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005710-Brass1">[37]</xref>
###xml 669 676 669 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 49 52 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 110 115 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 157 162 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 249 254 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 341 344 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 554 559 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Other studies that support a role for Tat-SF1 in HIV replication found that Tat-SF1 was upregulated in either HIV-1 gp120 stimulated primary T cells [57] or HIV-1 Nef overexpression in T cells [58]. The strongest validation of Tat-SF1's role in the HIV-1 lifecycle was revealed when it was identified in a large-scale, RNAi-based screen for HIV-dependency factors (HDFs) [37]. Despite the fact that these studies refer to Tat-SF1 as a Tat cofactor, their findings remain consistent with this protein being involved in the post-transcriptional control of HIV-1 RNA levels and further support the idea that Tat-SF1 depletion has a negative effect on the viral life cycle in vivo.
###end p 75
###begin p 76
###xml 494 502 494 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nef-hisD</italic>
###xml 466 471 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We thank Hal Bogard, Dr. Jennifer Lin Umbach, and Dr. Bryan Cullen for valuable reagents and technical advice. We thank Dr. Caroline LeSommer for her advice in the creation of the T-Rex-293 cell lines, and other members of the Garcia-Blanco lab for useful discussions and suggestions during the preparation of this manuscript. We also thank Tim Robinson and Dr. Matthew Marengo for their advice on stastical analysis. We thank Dr. Daniel Kuritzkes for providing the HIV-1 plasmid, pHIVenvBstEIInef-hisD, and Dr. Pinghuang Liu and Glenn Overman of the Duke Center for AIDS Research (CFAR) Molecular Virology Core for the replication-competent viruses and reverse transcriptase assays. The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: pSV-A-MLV-env from Dr. Nathaniel Landau and Dr. Dan Littman, pSG3Deltaenv from Drs. John C. Kappes and Xiaoyun Wu, and TZM-bl cells from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc.
###end p 76
###begin title 77
References
###end title 77
###begin article-title 78
###xml 48 53 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Control of RNA initiation and elongation at the HIV-1 promoter.
###end article-title 78
###begin article-title 79
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 auxiliary proteins: making connections in a dying cell.
###end article-title 79
###begin article-title 80
Mechanism of action of regulatory proteins encoded by complex retroviruses.
###end article-title 80
###begin article-title 81
Host factors exploited by retroviruses.
###end article-title 81
###begin article-title 82
Taking a new TAK on tat transactivation.
###end article-title 82
###begin article-title 83
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.
###end article-title 83
###begin article-title 84
Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor.
###end article-title 84
###begin article-title 85
###xml 28 56 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Specific interaction of the human immunodeficiency virus Tat proteins with a cellular protein kinase.
###end article-title 85
###begin article-title 86
###xml 21 26 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Direct evidence that HIV-1 Tat stimulates RNA polymerase II carboxyl-terminal domain hyperphosphorylation during transcriptional elongation.
###end article-title 86
###begin article-title 87
###xml 30 33 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro.
###end article-title 87
###begin article-title 88
Tat transactivation: a model for the regulation of eukaryotic transcriptional elongation.
###end article-title 88
###begin article-title 89
###xml 8 11 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines.
###end article-title 89
###begin article-title 90
###xml 38 41 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription.
###end article-title 90
###begin article-title 91
###xml 66 71 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages.
###end article-title 91
###begin article-title 92
Reversible phosphorylation of the C-terminal domain of RNA polymerase II.
###end article-title 92
###begin article-title 93
###xml 67 72 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tat-SF1: cofactor for stimulation of transcriptional elongation by HIV-1 Tat.
###end article-title 93
###begin article-title 94
###xml 104 139 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcription.
###end article-title 94
###begin article-title 95
###xml 70 75 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A novel RNA polymerase II-containing complex potentiates Tat-enhanced HIV-1 transcription.
###end article-title 95
###begin article-title 96
###xml 4 9 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The HIV-1 Tat cellular coactivator Tat-SF1 is a general transcription elongation factor.
###end article-title 96
###begin article-title 97
###xml 12 17 <span type="species:ncbi:9606">human</span>
###xml 33 38 <span type="species:ncbi:4932">yeast</span>
###xml 68 73 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Role of the human homolog of the yeast transcription factor SPT5 in HIV-1 Tat-activation.
###end article-title 97
###begin article-title 98
###xml 45 50 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Novel mechanism and factor for regulation by HIV-1 Tat.
###end article-title 98
###begin article-title 99
###xml 42 47 <span type="species:ncbi:9606">human</span>
Tat-SF1 protein associates with RAP30 and human SPT5 proteins.
###end article-title 99
###begin article-title 100
###xml 144 179 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Relief of two built-In autoinhibitory mechanisms in P-TEFb is required for assembly of a multicomponent transcription elongation complex at the human immunodeficiency virus type 1 promoter.
###end article-title 100
###begin article-title 101
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human transcription elongation factor CA150 localizes to splicing factor-rich nuclear speckles and assembles transcription and splicing components into complexes through its amino and carboxyl regions.
###end article-title 101
###begin article-title 102
p54(nrb) associates with the 5' splice site within large transcription/splicing complexes.
###end article-title 102
###begin article-title 103
Stimulatory effect of splicing factors on transcriptional elongation.
###end article-title 103
###begin article-title 104
###xml 8 13 <span type="species:ncbi:4932">yeast</span>
###xml 25 30 <span type="species:ncbi:9606">human</span>
CUS2, a yeast homolog of human Tat-SF1, rescues function of misfolded U2 through an unusual RNA recognition motif.
###end article-title 104
###begin article-title 105
FF domains of CA150 bind transcription and splicing factors through multiple weak interactions.
###end article-title 105
###begin article-title 106
Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells.
###end article-title 106
###begin article-title 107
Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes.
###end article-title 107
###begin article-title 108
###xml 52 87 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates.
###end article-title 108
###begin article-title 109
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.
###end article-title 109
###begin article-title 110
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import.
###end article-title 110
###begin article-title 111
###xml 18 52 <span type="species:ncbi:11908">human T-cell leukemia virus type I</span>
###xml 66 94 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range.
###end article-title 111
###begin article-title 112
###xml 95 110 <span type="species:ncbi:10090">transgenic mice</span>
A protocol for imaging alternative splicing regulation in vivo using fluorescence reporters in transgenic mice.
###end article-title 112
###begin article-title 113
###xml 15 50 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
###end article-title 113
###begin article-title 114
###xml 45 48 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Identification of host proteins required for HIV infection through a functional genomic screen.
###end article-title 114
###begin article-title 115
###xml 96 101 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.
###end article-title 115
###begin article-title 116
###xml 32 67 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).
###end article-title 116
###begin article-title 117
###xml 73 101 <span type="species:ncbi:12721">human immunodeficiency virus</span>
In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity.
###end article-title 117
###begin article-title 118
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism.
###end article-title 118
###begin article-title 119
A novel rapid assay for chloramphenicol acetyl transferase gene expression.
###end article-title 119
###begin article-title 120
###xml 61 66 <span type="species:ncbi:9606">human</span>
Analysis of the interaction of primate retroviruses with the human RNA interference machinery.
###end article-title 120
###begin article-title 121
###xml 14 19 <span type="species:ncbi:9606">Human</span>
###xml 51 56 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Initiation of Human Immunodeficiency Virus Type 1 (HIV-1) Transcription is Inhibited by Noncytolytic CD8+ Suppression.
###end article-title 121
###begin article-title 122
###xml 33 68 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Analysis of rev gene function on human immunodeficiency virus type 1 replication in lymphoid cells by using a quantitative polymerase chain reaction method.
###end article-title 122
###begin article-title 123
###xml 23 58 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
###end article-title 123
###begin article-title 124
###xml 75 110 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Negative and positive mRNA splicing elements act competitively to regulate human immunodeficiency virus type 1 vif gene expression.
###end article-title 124
###begin article-title 125
###xml 2 7 <span type="species:ncbi:9606">human</span>
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A human splicing factor, SKIP, associates with P-TEFb and enhances transcription elongation by HIV-1 Tat.
###end article-title 125
###begin article-title 126
###xml 105 140 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Coordination of transcription factor phosphorylation and histone methylation by the P-TEFb kinase during human immunodeficiency virus type 1 transcription.
###end article-title 126
###begin article-title 127
###xml 11 16 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 66 71 <span type="species:ncbi:9606">human</span>
Modulating HIV-1 replication by RNA interference directed against human transcription elongation factor SPT5.
###end article-title 127
###begin article-title 128
###xml 63 98 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Selectively reduced tat mRNA heralds the decline in productive human immunodeficiency virus type 1 infection in monocyte-derived macrophages.
###end article-title 128
###begin article-title 129
###xml 24 59 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity.
###end article-title 129
###begin article-title 130
###xml 25 60 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Diminished production of human immunodeficiency virus type 1 in astrocytes results from inefficient translation of gag, env, and nef mRNAs despite efficient expression of Tat and Rev.
###end article-title 130
###begin article-title 131
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication.
###end article-title 131
###begin article-title 132
###xml 55 58 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Genome-scale RNAi screen for host factors required for HIV replication.
###end article-title 132
###begin article-title 133
###xml 38 43 <span type="species:ncbi:4932">yeast</span>
An influenza virus replicon system in yeast identified Tat-SF1 as a stimulatory host factor for viral RNA synthesis.
###end article-title 133
###begin article-title 134
###xml 8 13 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 29 34 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Soluble HIV-1 gp120 enhances HIV-1 replication in non-dividing CD4+ T cells, mediated via cell signaling and Tat cofactor overexpression.
###end article-title 134
###begin article-title 135
###xml 105 108 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators.
###end article-title 135
###begin p 136
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 136
###begin p 137
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by a grant (R01-GM071037) to M.A.G-B., and a grant (R01-AI052779) to G.D.T. Work done through the Duke CFAR was supported by a grant (P30 AI 64518) and for the GHRB PhosphorImager Core by a NIAID contract (UC6 AI058607). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 137

